

Index

a

AAA domain-containing protein 2
(ATAD2) 88, 139, 348, 351,
353, 357, 359

acetyl-coenzyme A synthetase 2
(AceCS2) 191

acetylsine binding proteins 384

acetylome peptide microarray 109, 120

acetyltransferase activity 114, 301,
304–309, 319, 320, 326, 328

activity-based proteome profiling
(ABPP) 86, 87

acute erythroid leukemia (AEL) 241

acute megakaryoblastic leukaemia
(AMKL) 241

acute myeloid leukaemia (AML) 147,
239, 247, 252, 272, 310, 354, 401,
441

acute promyelocytic leukemia (APL)
232

4-acylpyrrole 359

ADP-ribosyltransferase 110, 187

affinity bead-based proteomic
approaches 138

3-alkyl dihydroxybenzoquinone embelin
321

α -ketoglutarate (α -KG) 62

α -methylene- γ -butyrolactone MB-3
324

AlphaScreen assay 364, 368, 387, 389,
406

α -tubulin 156, 177, 188, 190–192, 309,
324, 462, 463

amine oxidase domain (AOD) 62, 225,
229, 251

2-aminomethylpyridine-4-carboxylate
derivative 279

4-amino-1-naphthol 327

3-aminopyridine-4-carboxylic acids
273, 275

aminopyrrolidine moiety 408

androgen receptor (AR) 229, 277, 310,
312, 319, 327

armadillo repeat domain (ARD)
401–402

artemisinin combination therapy (ACT)
457

ATP-dependent remodelers 31–34

AutoDock 47, 52

azacitidine 433, 434, 441

azacytosine analogs 433

b

bacterial artificial chromosomes (BAC)
91

belinostat 26, 160, 466

5-benzamidonaphthalen-1/2-yloxy-
nicotinamide derivatives 57

2-(3-(benzyloxy)phenoxy)acetic acid
analogues 315

β -catenin 307, 326, 401, 402

β -mercaptoethanol 325

BET proteins 6, 86, 88, 90, 144, 146,
354, 355, 369

biochanin A 440

bioisosteres 273–275

bioluminescence resonance energy
transfer 139–141

biotin labeling 118

- 2,2'-bipyridine-4,4'-dicarboxylic acid scaffold 273
- bisguanidine 241
- bisnaphthalimidopropyl derivatives 467
- bisubstrate inhibitors 88, 313–315, 324, 325
- brain-derived neurotrophic factor (BDMF) 186
- bromodomain-containing protein 4 (BRD4) 119, 120, 140, 144, 146
- bromodomain/KAc-histone interaction 141
- bromodomains (BRDs) 120, 328
- cellular proliferation and tumorigenesis 348
 - chemoproteomics 88
 - and disease
 - BET-family 354–356
 - non-BET proteins 356–357
 - dual kinase-bromodomain inhibitors 365–369
 - epigenetic regulation 347
 - histone acetylation 347
 - human BRD family
 - druggability of 350–352
 - functions 352–353
 - K_{ac} binding site 348–350
 - inhibitors 138, 467
 - inhibitors, identification of
 - fragment-based lead discovery (FBLD) 359
 - high-throughput screening 357–359
 - ligand-based virtual screening (LBVS) 362–363
 - pharmacophore modelling 363
 - structure-based drug design (SBDD) 359–361
 - structure-based virtual screening (SBVS) 362
 - substructure searches 363–364
 - N1-aryl-propane-diamine 364
 - post-translational modifications 347
 - proteolysis targeted chimeras (PROTACs) 369–371
 - thienotriazolodiazepines 364
- C**
- cambinol 188, 190
- cancer 185, 187, 188, 190–192
- SIRT2 inhibition in 191
- carbamoyl phosphate synthetase 1 (CPS1) 187
- carboxylcytosine (caC) 424, 425
- cation- π interactions 62, 331, 384, 394, 406, 407
- C5-carboxylic acid 273–275
- CECR2-containing remodelling factor complex 353
- cellular thermal shift assay (CETSA) 139
- chemical probes
- biological research
 - affinity bead-based proteomics 138–139
 - bioluminescence resonance energy transfer 139–141
 - cellular nanoBRET assay 140
 - cellular systems 136
 - cellular target engagement 137–138
 - cellular thermal shift assay (CETSA) 139
 - chemical entities 134
 - and drug molecules 133
 - epigenetic signalling 134
 - fluorescence recovery after photobleaching (FRAP) 138
 - nonspecific toxicities 136
 - polypharmacology 133
 - potency and selectivity 134
 - protein-protein interactions 135
 - target-specific toxicities 136
 - technical and biological validation 133
 - epigenetics
 - histone acetylation and bromodomain 141–144
- chetomin 328

- chidamide 26, 160, 170
 ChIP-qPCR sequencing 239
N-[4-chloro-3-(trifluoromethyl)phenyl]-
 2-ethoxy-6-pentadecylbenzamide
 (CTPB) 318
 chromatin immunoprecipitation
 followed by sequencing
 (ChIP-seq) 265
 chromobox homolog (CBX) proteins
 395
 chromobox homologue 7 (CBX7)
 396–399
 chromodomain Y like protein 2
 (CDYL2) 399, 400
 cinnamate 236
 C–N bond cleavage reactions 224
 comparative molecular similarity indices
 analysis (CoMSIA) 47
 computer-based methods, in drug
 discovery
 binding affinities 49
 docking 47
 pharmacophore-based methods
 46–47
 QSAR 47
 virtual screening 48
 CpG dinucleotides 422, 459
 CpG-island methylator phenotype
 (CIMP) 357
 curcumin 319
 cutaneous T cell lymphoma (CTCL) 6,
 160, 161
 cyclin-dependent kinase (CDK)
 inhibitor 311, 366
 cyclopropanation 236
 Cytosine, modifications of 424–426
- d**
- D-amino acid oxidase 239
 data-independent acquisition (DIA)
 81, 82
 decitabine 433, 436, 441–443
 demethylase chemoproteomics 88
 demethylase inhibitors 88
 demethylation
 LSD mediated 226
 nucleophilic 221, 223
 oxidative mechanisms 223
 diaryl heterocycles 246, 247
 diazene 234
 dichlone 437
 diethyl pentadecylidenemalonate 318
 1,4-dihydropyridines (DHPs) 192
 dihydropyrrolidine inhibitor 250
 dihydroquinazolinone (DHQ) 331, 359
 dimethoxybenzene 398
 dinaciclib 366, 368
 di-*N*-desethylamiodarone 401
 DNA methylation 14, 459
 biochemical modification 422
 in disease 432
 mechanism of 430–431
 physiological role of 431–432
 DNA nucleotide methyltransferases
 (DNMTs) 460
 covalent inhibition of 435
 DNMT1 426, 427, 429, 430
 DNMT2 426, 427
 DNMT3A 426–429
 DNMT3B 426, 427
 DNMT3C 426
 DNMT3L 426–428
 inhibitors
 non-nucleosidic 436–441
 nucleoside-mimicking 433–436
 therapeutic applications of
 441–442
 methylation reaction 423
 mouse DNMT1 429
 double-stranded β -helix (DSBH) 264,
 265
 drug resistance 169, 281, 310, 432, 458
- e**
- E-cadherin 232, 246
 embryonic ectoderm development
 (EED) protein 19, 405
 entinostat 160, 170–172, 179, 234
 epidermal growth factor receptor
 (EGFR) 169, 369
 epidithiodiketopiperazine moiety 328

- epigallocatechin-3-gallate (EGCG) 319, 437
- epigenetics
- ATP-dependent remodelers 31–34
 - bio-medical applications 4
 - definition 3
 - DNA demethylating agents 4
 - DNA methylation 14–16
 - Isocitrate dehydrogenases (IDH) genes 5
 - double-stranded DNA 107
 - epidrugs 4
 - HDAC inhibitors 4
 - histone acetyltransferase (HAT) enzymes 24–26
 - histone acylations 108
 - histone arginine methyltransferases 16–17
 - histone crotonylation readers and 53BP1-nucleosome 35–37
 - histone deacetylases 26–28
 - histone lysine methyltransferases 17–21
 - histone lysine ubiquitinylases 21–22
 - histone molecules 107
 - histone variants and histone chaperones 28–31
 - hydroxymethyl cytosine 5
 - identification of 4
 - modification 4
 - peptide microarrays
 - histone code erasers 114–117
 - histone code writers 110–113
 - post-translational modifications (PTMs) 107
 - histone code readers 119–121
 - SAGA deubiquitination module 22–24
 - TET enzymes 5
- f**
- factor inhibiting hypoxia-inducible factor (FIH) 64, 266, 277
 - ferrous iron (Fe(II)) 264
 - flavin adenine dinucleotide (FAD) 224, 239, 244, 263
 - FlexX program 50
 - fluorescence polarization (FP) 285, 357, 393
 - fluorescence recovery after photobleaching (FRAP) 138, 142, 144, 145, 390
 - fluorescence scanning 118
 - fluorescence thermal shift assay 408
 - formylcytosine (fC) 424, 425
 - fragment-based lead discovery (FBLD) 357, 359
 - fragment screening approach 327, 402
- g**
- genistein 440, 442
 - genome-wide localisation studies 265
 - glucokinase regulatory protein (GKRP) 187
 - glutamate dehydrogenase (GDH) 187
 - green fluorescent protein (GFP) 138, 390
- h**
- hepatoma-derived growth factor (HDGF) 391
 - high-throughput screening 357–359
 - histone acetyltransferases
 - bisubstrate inhibitors 313–315
 - in diseases 309–312
 - enzymes and families 298–299
 - ESA1 308
 - GCN5L1 304
 - GNAT superfamily 299
 - KAT1/Hat1 303
 - KAT2A/GCN5 and KAT2B/PCAF 301
 - KAT3A/CBP and KAT3B/p300 family 304–306
 - KAT5/Tip60 306–307
 - KAT6A/MOZ, KAT6B/MORE, and KAT7/HBO1 307
 - KAT8/MOF 307–308
 - modulators 312–313
 - MYST family 306–309

- natural products and synthetic analogues and derivatives 315–321
 - nuclear hormone receptors 308
 - protein–protein interaction domains 328–333
 - SAS2 and SAS3 308
 - synthetic compounds 321–328
 - histone acetyltransferases (HATs) 24–26, 137, 297, 309, 462
 - histone acylations 108, 221, 306
 - histone code 45, 91, 107–110, 112, 114–117, 119–121, 124, 347, 393, 421
 - histone deacetylases (HDACs) 141, 230, 234, 247
 - inhibitors 421, 442, 443
 - zinc-dependent HDACs
 - benzhydroxamates 53
 - Virtual screening campaign 53
 - cocrystallized inhibitors 50
 - deacetylase active site 50
 - FlexX program 50
 - fragment-based drug design 56
 - hydroxamic acid 49
 - ligand-bound structures 50
 - monodentate binding mode 50
 - nanomolar HDAC inhibitors 52
 - pharmacophore-based modelling 50
 - Rossmann fold domain 54
 - SAHA and Nexturastat A 52
 - SirReal2 57
 - sirtuins 54–58
 - structure-based design approach 52
 - histone demethylases
 - Jumonji-type demethylases 64–66
 - LSD1 (KDM1A) 62–64
 - histone lysine methyltransferases 17–21, 263
 - histone methyltransferases
 - arginine and lysine methyltransferases 61
 - benzoxazole and benzimidazole derivatives 61
 - human lysine methyltransferases 58
 - MM-GB/SA protocol 59
 - pharmacophore filtering and visual analysis 61
 - pharmacophore prefilter 59
 - PRMTs and inhibitors 59
 - S-adenosylmethionine (SAM) 58
 - structure–activity relationship (SAR) exploration 61
 - van der Waals interactions 59
 - histone modifications 35, 45, 79, 91, 92, 97, 107, 230, 286, 347, 354, 421, 424, 460, 461
 - histone modifying enzymes (HME)
 - structure-based approaches 464–465
 - therapeutic targets 462–464
 - histone posttranslational modifications 91–97, 458, 460–461
 - HIV-1-TAT protein 310, 333
 - homogeneous time-resolved fluorescence (HTRF) method 406
 - honokiol 192
 - human epidermal growth factor receptor 2 (HER2) 169
 - human immunodeficiency virus (HIV) protein 310, 392
 - Huntington's disease (HD) 5, 7, 176, 185
 - hydroxamates 27, 53, 169, 176, 179, 282, 468
 - hydroxamic acids 50, 52, 53, 158, 169, 173, 176, 273
 - hydroxymethylcytosine (hmC) 424, 425
 - hydroxynaphthoquinone plumbagin 320
 - (*z*)-2-hydroxy-6-(4-(pentylloxy)styryl) benzoic acid 318
- i**
- 3,5-imidazolidinedione inhibitor 327
 - mixed lineage leukemia (MLL) 232
 - International Human Epigenome Consortium (IHEC) 3

isogarcinol 320

isoxazoline 437

j

JAK2 inhibitors 368

JmjC histone lysine demethylases
263

and development and disease
266–272

generic inhibitors 282–283

and histone lysine methylation
265–266

histone substrate competitive
inhibitors

allosteric inhibitors 276

peptide inhibitors 276

small molecule inhibitors 276

KDM2/7 and KDM3 targeted
inhibitors 282

KDM4 subfamily targeted inhibitors
277–279

KDM4/5 subfamily targeted
inhibitors 279–280

KDM5 subfamily targeted inhibitors
280–281

KDM6 subfamily targeted inhibitors
281–282

plant homeodomain fingers (PHD
fingers) 284–286

selectivity and potency, in cells
283–284

2OG oxygenase inhibitors

α -keto acid moiety 273

bioisosteres 273

metal-quenching effect 273

mimicking scaffolds 273

Tudor domains 286

Johnson–Corey–Chaykovsky reaction
236

Jumonji C domain (JmjC) 223

Jumonji-type demethylases 64

jumonobead affinity matrix 88

k

Kinetoplastid gene transcription 460

l

ligand-based virtual screening (LBVS)
362–363

long-chain alkylidenemalonates
(LoCAMs) 319

lysine acetylation 24, 45, 94, 141, 297,
301, 310–312, 319, 460, 461

lysine reader proteins

chromodomain group 395–400

human MBT domain family
385–387

PWWP domain 390–392

Royal family 385

Tudor domain 392–395

WD40 repeat domain family
402–404, 406

lysine-specific demethylase (LSD)

discovery and mechanistic features
AOD 225

catalytic mechanism of 226

CoREST 225, 227

FAD-dependent oxidoreductases
224

JmjC 223

LSD1 223, 225

LSD2 225

MAOs 224

function and dysfunction

APL 232

binding partners 230, 231

evolutionary conservation of 229

MLL 232

N-terminal sequences 231

PPAR&LWx0F061 232

Snail transcription factors 232

SREBPs 232

tretinoin 232

in vitro and in vivo models 232

Warburg effect 232

inhibitors

cell-free enzymatic assays 233

clinical development 253

irreversible small molecule, MAO
inhibitors 233–241

mass spectrometric analysis 233

peptide 250

- reversible small molecule
 - 241–248
- synthetic macromolecular
 - 248–251
- substrates
 - AR 229
 - ER 229
 - protein 230
 - X-ray structure 227–229
- lysyl oxidases 114
- m**
- manganese superoxide dismutase
 - (MnSOD) 187, 192
- mass spectrometry (MS) analysis
 - chemoproteomics
 - activity-based proteome profiling
 - (ABPP) 86
 - BET proteins 86
 - bromodomain chemoproteomics
 - 88
 - demethylase chemoproteomics
 - 88
 - histone deacetylase and
 - acetyltransferase
 - chemoproteomics 87–88
 - methyltransferase
 - chemoproteomics 89
 - phosphatidyl inositol-3-kinase
 - (PI3K) inhibitor 86
 - SAR-preserving linkage 85
 - structure-activity relationship
 - (SAR) 85
 - epigenetic drug discovery
 - affinity enrichment, histone tail
 - peptides 91
 - bottom-up proteomics methods
 - 80
 - chromatin-modifying enzymes 79
 - co-eluting and co-ionizing peptides
 - 83
 - C18 resins 80
 - data-dependent acquisition (DDA)
 - 81
 - data-independent acquisition
 - (DIA) workflows 82
 - genomic and antibody-based
 - strategies 79
 - immunoaffinity purification
 - 89–90
 - MALDI-ToF based cell assays 98
 - MSI 83–85, 98
 - peptide-spectrum match (PSM)
 - 81
 - SRM experiment 82
 - synthetic reference peptides 83
- histone post-translational
 - modification
 - C18 chromatographic resins 92
 - chromatin
 - immunoprecipitation-DNA
 - sequencing (ChIP-Seq)
 - experiments 98
 - EZH2 inhibitor GSK126 and the
 - EZH1/EZH2 dual inhibitor 96
 - G9A/GLP inhibitors BIX01294 and
 - UNC0638 95
 - genetic RNA interference (RNAi)
 - approach 96
 - genomic distribution 97
 - identical fragmentation patterns
 - and chromatographic retention
 - 97
 - lysine acetyltransferases and
 - deacetylases 96
 - protein-level derivatization 94
 - quantitative accuracy 95
 - quantitative mass spectrometry
 - 95
 - synthetic reference peptides and
 - biological functions 97
 - post-translational modifications
 - (PTMs) function 79
- mass spectrometry imaging (MSI)
 - 83–85, 98–99
- matrix-assisted laser
 - desorption/ionization (MALDI)
 - 83, 84
- methylation 221
 - epigenetic DNA and protein 222
- 5-methylcytosines 14, 422, 424, 425
- methyllysine reader proteins 384

- methyltransferase chemoproteomics
89
- mithramycin A 440
- molecular oxygen (O₂) 225, 264
- monoamine oxidases (MAOs) 224,
232, 233, 242, 263
- n**
- nanaomycin A 440
- N-cadherin 246
- neurodegeneration 188, 193
- neuroLSD1 229
- nexturastat A 28, 50–52
- nicotinamide 49, 54, 56, 57, 155, 186,
190
- nicotinamide phosphoribosyl
transferase (NAMPT) 186
- N⁶-methyl-lysine oxidase enzyme 223
- N,N-dimethylbenzimidazolone
structural class 360
- non-nucleosidic DNMT inhibitors
436–441
- N-terminal acetyltransferase (NAT)
299, 300
- N-[1,3,4]thiadiazol-2-yl sulfonamide
52
- nucleophilic demethylation 221
- nucleoporin protein 98 (NUP98) 285,
401
- nucleoside-mimicking DNMT
inhibitors 433–436
- nucleosome remodelling and
deacetylase (NuRD) complex
353
- o**
- oligomycin-sensitivity conferring
protein (OSCP) 192
- ortho*-aminoanilides 159, 160,
170–172
- oxazoline 437
- 2-oxoglutarate (2OG) 65, 264, 273
- p**
- pan-assay interference compounds
(PAINS) 48, 50
- panobinostat 26, 50, 98, 139, 160, 234,
466, 468
- parasite epigenetic targets
clinical trials 458
DNA methylation 459–460
epidrugs
high throughput screening 467
repurposing 466–467
structure-based development
467–468
genome sequencing 458
histone modifying enzymes 462
histone posttranslational
modifications 460–461
intracellular protozoan parasites
459
- Parkinson's disease (PD) 5, 56, 185,
186, 188
- p53 controlled promoter sites 331
- peptidomimetic inhibitors 396, 397,
404
- peroxisome proliferator-activated
receptor α 232
- phenelzine 233, 234
- phenotypic screening assays 279
- 4-phenylpiperidine 280
- phosphatidyl inositol-3-kinase (PI3K)
inhibitor 86
- phosphorimaging 110, 112
- phosphorylations 107, 108, 112, 121,
124
- piperazine moieties 398
- plant homeodomain (PHD) 26,
284–286, 352, 385, 400
- pleckstrin homology domain-interacting
protein (PHIP) 350–353
- pleiotropic effects 315, 319
- polo-like kinase 1 (PLK1) 277, 368
- polycomb repressive complex 1 (PRC1)
21, 22
- polycomb repressive complex 2 (PRC2)
19, 91, 141, 204, 394
- polyisoprenylated benzophenone
garcinol 320
- polymyxin B 244

- post-translational modifications (PTMs) 79, 107
- praziquantel (PZQ) 458
- proline glutamic acid and leucine-rich protein 1 (PELP1) 229
- prolyl hydroxylase domain-containing proteins (PHDs) 64, 286
- protein arginine methyltransferases (PRMTs) 16, 58, 201, 211–215, 265, 392
- protein lysine methyltransferases (PKMTs) 201
- protein methyltransferases (PMTs)
lysine methyltransferases (KMTs)
gene expression and transcription 202
- H3K4 and H3K36 methyltransferases 206–208
- H3K9 methyltransferases 202–204
- H3K27 methyltransferases 204–206
- H3K79 methyltransferases 210–211
- H4K20 methyltransferases 208–210
- protein arginine methyltransferases (PRMTs)
CARM1 inhibitors 213–214
PRMT1 inhibitors 211–212
PRMT3 inhibitors 212–213
PRMT5 inhibitors 214
PRMT6 inhibitors 214–215
- proteolysis targeting chimeras (PROTAC) 7, 57, 369–372
- pyrazolopiperidine 146, 332
- pyrazolopyrimidine moiety 366–368
- pyridine-N-oxide 367
- q**
- quantitative structure-activity relationship (QSAR) techniques 47
- quinazoline 61, 204, 241, 276, 358, 466
- Quisinstat 466
- r**
- regulator of G-protein signaling 4 (RGS4) gene 332
- replication focus targeting domain (RFS) 427
- REST corepressor 1 (Rcor1) 225, 227, 231
- resveratrol 191, 192
- rimonabant 326
- rocilinostat 160, 176
- romidepsin 26, 160, 466, 468
- Rossmann fold domain 54
- Rubinstein–Taybi syndrome (RTS) 144, 310, 357
- s**
- S-adenosylmethionine (SAM) 17, 19, 58, 110, 422
- SAHA 26, 52, 87
- sexual differentiation 461
- single electron transfer (SET) 225, 234
- single nucleotide polymorphism (SNP) analysis 356, 388
- SIRT1 activators 6, 192
- SIRT inhibitors (SIRTi)
AGK2 188
AK-7 191
cambinol 188
EX-527 188
HR-73 188
peptides and pseudopeptides 191
salmeterol 189
SirReal2 190
sirtinol 189
splitomicin 188
tenovin-1 188
tenovin-6 188, 189
- sirtinol 186, 189, 190
- sirtuin 2 activity 114
- sirtuins (SIRTs) 54–58, 114, 121, 185, 462, 463
biological functions of 185–187
discovery of 185
modulators
activators 191–192
SIRTi 189

- sirtuins (SIRT6) (*contd.*)
- small cell lung cancer (SCLC) 233, 239, 241, 252
- splitomicin 188
- sterol regulatory element-binding proteins (SREBPs) 232
- stimulatory recognition motif (SRM) 20–21, 82, 406
- strand switching regions (SSR) 460
- Structural Genomics Consortium (SGC) 142, 147
- structure-activity relationship (SAR) 61, 85, 140, 185, 190, 273, 369, 437
- structure-based drug design (SBDD) 47, 50, 54, 357, 359–361, 464
- structure-based virtual screening (SBVS) 361–364
- suppressor of zeste 12, 19
- suramin 56, 190, 397
- symmetrically dimethylated arginine (sDMA) 109, 201
- t**
- tacedinaline 179
- tandem mass spectrometry analysis 81, 283
- target recognition domain (TRD) 427, 429, 430
- T-cell acute lymphoblastic leukemia (T-ALL) 282
- T. cruzi* overexpression of bromodomain factor 3 (*TcBDF3*) 463
- ten-eleven translocation (TET) enzymes 424, 425
- tenovin-1 188
- tenovin-6 188
- tetrahydroquinoline (THQ) 331, 358, 369
- tetrazoles 275
- TFIID subunit 1 (TAF1) 353
- thermal proteome profiling (TPP) 98
- thienotriazolodiazepines (TTDs) 364–365
- time resolved fluorescence resonance energy transfer (TR-FRET) 142, 326, 359, 408
- transcription start site (TSS) 239, 266, 354, 461
- tranylcyproline 62, 225, 233–239, 241, 242, 250
- triazole 246, 282, 365
- trichostatin A (TSA) 45, 158, 234, 466
- trifluoroacetylthiophene 175, 176
- trifluoromethyl ketones 175, 176
- trifluoromethylxadiazole class IIa inhibitors 176
- trimethylamiodarone 401
- trimethylated lysines 118, 266, 284
- trimethyllysine 225, 396, 400
- tubacin 176, 177
- tubastatin A 54, 176
- Tudor domain 26, 36, 37, 139, 284, 286, 392–395, 401, 402
- typical bromodomains 349, 350
- tyrosine phosphorylation 112
- u**
- US Food and Drug Administration (FDA) 160
- v**
- valproate 160
- variable surface glycoprotein (VSG) 460, 462, 463, 467
- virtual screening 48, 214, 244, 245, 324, 357, 362–364, 406, 437, 441
- von Hippel–Lindau (VHL) 370
- vorinostat 26, 87, 160, 169, 173, 234, 466, 468
- w**
- WD40 repeat protein 5 (WDR5) 403–405
- Wnt/ β -catenin signaling 325, 326, 401
- y**
- yeast phenotypic screenings 324
- z**
- zebularine 436
- zinc-dependent histone deacetylases class I inhibitors 169–174

- class IIa inhibitors 174–176
- class IIb inhibitors 176–177
- clinical use and development
160–169
- enzymatic mechanism 156
- HDAC1–3 inhibitors 170–173
- HDAC8 inhibitors 173–174
- pharmacophore model 158
- trapoxin B 158
- trichostatin A 158
- types of inhibitors 158

